Advertisement

Neues zum Wirkmechanismus von BCG beim oberflächlichen Harnblasenkarzinom

  • A. Böhle
Conference paper

Zusammenfassung

Die intravesikale Immuntherapie des oberflächlichen Urothelkarzinoms der Harnblase mit Bacillus Calmette-Guérin (BCG) wird seit 1976 klinisch durchgeführt (Morales et al. 1976). Der wissenschaftliche Weg hierhin war nicht zufällig, sondern basierte auf ausgedehnten sorgfältigen Voruntersuchungen mehrerer Arbeitsgruppen. Aus der Fülle der zugrundeliegenden wissenschaftlichen Daten sollen deshalb zunächst einige Ergebnisse dargestellt werden, welche als Grundlage für das Verständnis weiterer aktueller Untersuchungen dienen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Böhle A, Gerdes J, Nowc C, Ulmer AJ, Musehold J, Hofstetter AG, Flad H-D (1990a) Effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of monouclear cells. In: deKernion JB (Ed) Immunotherapy of urologic tumours. Churchill Livingstone, New York, pp 83–106Google Scholar
  2. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D (1990b) Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53–58PubMedGoogle Scholar
  3. Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D (1990c) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette- Guerin in immunotherapy. J Urol 144: 59–64PubMedGoogle Scholar
  4. Böhle A, Wang M-H, Flad H-D, Ulmer AJ (1991) In vitro cellular cytotoxicity against human bladder carcinoma cell lines. In: Jocham D, Thüroff JW, Rübben H (Eds) Investigative Urology 4. Springer, Berlin, pp 131–139Google Scholar
  5. Böhle A, v.d.Sloot E, Richter E, Gerdes J, Wood WG, Jocham D (1993) Binding to Fibronectin (FN) — a prerequisite step? Investigations on the role of FN in intravesical BCG immunotherapy. In: Thüroff JW, Rübben H, Rassweiler J (Eds) Investigative Urology 5. VHC Edition Medizin, Weinheim (im Druck)Google Scholar
  6. Grimm EA, Rosenberg SA (1984) The human lymphokine-activated killer cell phenomenon. Lymphokines 9: 279–311Google Scholar
  7. Hanna MG, Zbar B, Rapp HJ (1972) Histopathology of tumor regression after intralesional injection of mycobacterium bovis. II. Comparative effects of Vaccinia virus, oxazolone, and turpentine. J Natl Cancer Inst 48: 1697PubMedGoogle Scholar
  8. Herr HW, Whitmore WF (1987) Ureteral carcinoma in situ after sucessful intravesical therapy for superficial bladder tumors: Incidence, possible pathogenesis and management. J Urol 138: 292–294PubMedGoogle Scholar
  9. Kavoussi LR, Brown WJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin Bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response. J Clin Invest 85: 62–67PubMedCrossRefGoogle Scholar
  10. Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM (1985) Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J Urol 134: 48–53PubMedGoogle Scholar
  11. Lamm DL, Reichert DF, Harris SC, Lucio RM (1982) Immunotherapy of murine transitional cell carcinoma. J Urol 128:1104–1108PubMedGoogle Scholar
  12. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180–183PubMedGoogle Scholar
  13. Ratliff TL, Gillen D, Catalona WJ (1987a) Requirement of a thymus-depend- ent immune response for BCG-mediated antitumor activity. J Urol 137: 155–158PubMedGoogle Scholar
  14. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987b) Intravesical BCG therapy for murine bladder tumors: Initiation of the response by fibronectin- mediated attachment of BCG. Cancer Res 47: 1762–1766PubMedGoogle Scholar
  15. Ratliff TL, Kavoussi L, Catalona WJ (1988a) Role of fibronectin in intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 139: 410–414PubMedGoogle Scholar
  16. Ratliff TL, McGarr JA, Abou-Zeid C, Rook GAW, Stanford JL, Aslanzadeh J, Brown EJ (1988b) Attachment of mycobacteria to fibronectin-coated surfaces. J Gen Microbiol 134: 1307–1313PubMedGoogle Scholar
  17. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res 43: 1611–1615PubMedGoogle Scholar
  18. V. d. Sloot E, Küster S, Böhle A, Bruan J, Wood WG (1992) Towards an understanding of the mode of action of bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur J Clin Chem Clin Biochem 30: 503–511PubMedGoogle Scholar
  19. Zbar B, Bernstein ID, Rapp HJ (1971) Suppression of tumor growth at the site of infection with living BCG. J Natl Cancer Inst 46: 831–839PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • A. Böhle
    • 1
  1. 1.Klinik für UrologieMedizinische Universität zu LübeckLübeckDeutschland

Personalised recommendations